Walvax Biotechnology Co., Ltd. 300142.SZ

Name: 300142.SZ quality scores
Creator: Stocktoria
License: https://stocktoria.com/terms/

CN · XSHE · XSHE · stock · Healthcare · website

Walvax Biotechnology Co., Ltd. (300142.SZ) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.14% (safety: safe). FY2025 revenue was CN¥2.4B at a 7.4% net margin.

Chart by TradingView

7/9

Piotroski F — financial health

5.95

Altman Z″ — distress risk · safe

16.3%

Dividend payout · safe

CN¥13.35 as of 2026-07-01 · +6.3% 1y

CN¥10.91CN¥13.3552-wk

Market cap USD$3.1B

P / E120.1×

Dividend yield0.14%

Net margin7.4%

Return on equity2.1%

Beta0.39

Employees1,981

Analyst price target

CN¥8.00 -40.1% vs last

· 1 analysts

range CN¥8.00 – CN¥8.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

About Walvax Biotechnology Co., Ltd.

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.

Revenue trend · last 4y · down

How it ranks in Healthcare · percentile among 73 companies

Piotroski Fstronger than 58%

Net marginstronger than 31%

Return on equitystronger than 7%

Revenue growthstronger than 1%

Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 7/9 tests passed

Positive return on assets
Positive operating cash flow
Rising ROA
Cash flow exceeds net income
Lower long-term debt
Rising current ratio
No share dilution
Rising gross margin
Rising asset turnover

Altman Z″ components · safe zone

Component	Value
Working capital / assets	0.216
Retained earnings / assets	0.237
EBIT / assets	0.028
Equity / liabilities	3.402

FAQ

Is 300142.SZ financially healthy?

Walvax Biotechnology Co., Ltd.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does 300142.SZ pay a dividend, and is it safe?

Yes. Walvax Biotechnology Co., Ltd. pays a dividend yielding about 0.14% with a 16.3% payout ratio, rated “safe” for safety.

How profitable is 300142.SZ?

In FY2025, Walvax Biotechnology Co., Ltd. had a net margin of 7.4% and a return on equity of 2.1%.

Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.